LTM1201LB

LTM1201LB is an experimental pharmacological agent being investigated for the treatment of obstructive sleep apnea (OSA). It is part of a series of compounds (including LTM1201L, LTM1201LN, and LTM1201LD) developed or studied by researchers at Brigham and Women's Hospital. The drug is designed to pharmacologically activate the hypoglossal motor nucleus, which controls the genioglossus muscle, the primary dilator of the upper airway. By increasing upper airway muscle tone during sleep, LTM1201LB aims to reduce the collapsibility of the airway and decrease the severity of OSA. This approach typically involves the use of noradrenergic and/or antimuscarinic agents to compensate for the loss of muscle activity that occurs at sleep onset.

Other names

LTM1201LBLTM-1201LBLTM 1201LB